8-K: Biora Therapeutics to be Delisted from Nasdaq Following Non-Compliance

Biora Therapeutics will be delisted from the Nasdaq due to non-compliance with market value requirements and will begin trading on the OTC Markets.

Summary

• Biora Therapeutics received a formal notice from Nasdaq on December 9, 2024, stating that its securities will be delisted.
• The delisting is due to the company's failure to meet the market value of listed securities requirement for continued listing on The Nasdaq Global Market.
• Trading of Biora's securities on Nasdaq will be suspended effective at the open of business on Wednesday, December 11, 2024.
• Following the suspension, Nasdaq will file a Form 25 with the SEC to formally delist the company's securities.
• Biora Therapeutics anticipates that its shares will begin trading on the OTC Markets OTC Pink Current Information tier under the symbol BIOR, concurrent with the Nasdaq suspension.

Sentiment

Score: 2

Explanation: The document reports a significant negative event for the company, namely its delisting from Nasdaq, which is likely to negatively impact investor sentiment.

Negatives

• Biora Therapeutics failed to meet the market value requirements for continued listing on the Nasdaq Global Market.
• The company's securities will be delisted from Nasdaq, which may negatively impact investor confidence and liquidity.

Risks

• The delisting from Nasdaq could lead to decreased visibility and potentially lower trading volume for Biora's stock.
• Trading on the OTC Markets may result in less stringent regulatory oversight and potentially higher volatility.
• The company's ability to raise capital may be affected by the delisting.

Future Outlook

Biora Therapeutics anticipates its shares will begin trading on the OTC Markets OTC Pink Current Information tier under the symbol BIOR, concurrent with the Nasdaq suspension.

Management Comments

• Adi Mohanty, Chief Executive Officer, signed the report on behalf of Biora Therapeutics.

Industry Context

Delistings from major exchanges like Nasdaq can occur when companies fail to meet listing requirements, often due to declining market capitalization or other financial issues. This is not uncommon in the biotech sector, where companies can face challenges in achieving commercial success and maintaining investor confidence.

Comparison to Industry Standards

• Delisting from Nasdaq is a significant negative event for a company, as it typically indicates a failure to meet minimum financial or operational standards.
• Companies like Biora that move to the OTC markets often experience reduced trading volume and investor interest compared to those listed on major exchanges.
• Other biotech companies that have faced similar delisting issues include those with unsuccessful clinical trials or financial difficulties, such as [hypothetical company A] and [hypothetical company B], which also moved to the OTC markets after failing to meet Nasdaq's listing requirements.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty regarding the company's future.
• The company's ability to attract future investment may be negatively impacted.

Next Steps

• Biora Therapeutics will transition to trading on the OTC Markets OTC Pink Current Information tier.
• Nasdaq will file a Form 25 with the SEC to formally delist the company's securities.

Key Dates

Keywords

delisting, Nasdaq, OTC Markets, market value, BIOR, securities, non-compliance